Skip to main content

BASEL, Switzerland (

TheStreet

) --

Roche

, the Swiss drugmaker, said Thursday it expects at least high single-digit sales growth for its pharmaceuticals division in 2009 after third-quarter sales rose 14%.

Roche said Tamiflu sales rose to 994 million Swiss francs ($982.1 million) and it raised its full-year forecast for the drug to about 2.7 billion francs from 2 billion.

Roche said its third-quarter sales were 12.4 billion francs.

Third-quarter sales of cancer drug Avastin rose 21% to 1.59 billion francs from a year earlier.

Roche CEOe Severin Schwan said the integration of U.S. biotech company

TheStreet Recommends

Genentech

was progressing well.

-- Reported by Joseph Woelfel in New York

.

Follow TheStreet.com on

Twitter

and become a fan on

Facebook.

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.